Stocky turns companies like PHARMA MAR SA PHARMA MAR ORD SH into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Cautious. 0RC6.L scores mid-range on growth (50.5/100) and value (50/100) metrics, suggesting neither compounder nor deep value characteristics. Leadership alignment is modest (59/100), with limited founder-CEO overlap or capped dilution signals. The decisive concern: Vulnerability Index of 100 driven by weak financial buffer—thin cash reserves or high leverage limit margin for error, making this firm sensitive to revenue disruption or rising rates despite any operational merit.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for PHARMA MAR SA PHARMA MAR ORD SH:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 57/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates PHARMA MAR SA PHARMA MAR ORD SH (0RC6.L) at 57/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. 0RC6.L scores mid-range on growth (50.5/100) and value (50/100) metrics, suggesting neither compounder nor deep value characteristics. Leadership alignment is modest (59/100), with limited founder-CEO overlap or capped dilution si
0RC6.L's current Stocky Verdict is 57/100, placing it in the "Cautious" band. This composite combines a 51/100 Compounder score, 59/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for PHARMA MAR SA PHARMA MAR ORD SH yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
PHARMA MAR SA PHARMA MAR ORD SH scores 59/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
PHARMA MAR SA PHARMA MAR ORD SH's Vulnerability Profile scores 100/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to PHARMA MAR SA PHARMA MAR ORD SH.
Sign up free and unlock the full analysis on 0RC6.L — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for 0RC6.L in the app.
